Modality
Vaccine
MOA
CAR-T BCMA
Target
CGRP
Pathway
mTOR
Hemophilia A
Development Pipeline
Preclinical
~Oct 2015
→ ~Jan 2017
Phase 1
~Apr 2017
→ ~Jul 2018
Phase 2
Oct 2018
→ Feb 2030
Phase 2Current
NCT04769839
2,131 pts·Hemophilia A
2020-08→TBD·Completed
NCT05183810
961 pts·Hemophilia A
2018-10→2030-02·Not yet recruiting
3,092 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-02-113.9y awayPh2 Data· Hemophilia A
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P2
Not yet…
P2
Complet…
Catalysts
Ph2 Data
2030-02-11 · 3.9y away
Hemophilia A
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04769839 | Phase 2 | Hemophilia A | Completed | 2131 | SeizFreq |
| NCT05183810 | Phase 2 | Hemophilia A | Not yet recr... | 961 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| LEG-9870 | Legend Biotech | Phase 1 | CGRP | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn |